Trial Profile
A Single-arm Phase II Trial Investigating the Efficacy and Safety of Zalutumumab in Patients With Non-Small Cell Lung Cancer Who Have Progressive Disease After Treatment With Tyrosine Kinase Inhibitors
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 13 Oct 2011
Price :
$35
*
At a glance
- Drugs Zalutumumab (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Sponsors Genmab
- 13 Oct 2011 New trial record